{"cluster": 66, "subcluster": 3, "abstract_summ": "These data demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates.One Sentence Summary A purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc) confers complete protection in non-human primates against SARS-CoV-2 strains circulating worldwide by eliciting potent humoral responses devoid of immunopathologyThe spread of the SARS-CoV-2 into a global pandemic within a few months of onset motivates the development of a rapidly scalable vaccine.Here we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates.Here we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates.Taken together, the presented respiratory vaccine candidate is highly attenuated in primates per se, safe and lacking pre-existing immunity in human, and carries the potential for accelerated vaccine development against CoVID-19 for clinical studies.", "title_summ": "A Scalable Topical Vectored Vaccine Candidate Against SARS-CoV-2Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody ResponseRapid development of an inactivated vaccine for SARS-CoV-2Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine induces equivalent preclinical antibody titers and viral neutralization to recovered COVID-19 patientsSARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in miceA single dose of recombinant VSV-\u0394G-spike vaccine provides protection against SARS-CoV-2 challengeDevelopment of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2A universal design of betacoronavirus vaccines against COVID-19, MERS and SARSSelf-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in miceSingle-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primatesDNA vaccine protection against SARS-CoV-2 in rhesus macaquesSARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen PreparednessDevelopment of an inactivated vaccine candidate for SARS-CoV-2", "title_abstract_phrases": "Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody ResponseThere is a great need for the development of vaccines for preventing SARS-CoV-2 infection and mitigating the COVID-19 pandemic.These data demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates.One Sentence Summary A purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc) confers complete protection in non-human primates against SARS-CoV-2 strains circulating worldwide by eliciting potent humoral responses devoid of immunopathologySelf-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine induces equivalent preclinical antibody titers and viral neutralization to recovered COVID-19 patientsThe spread of the SARS-CoV-2 into a global pandemic within a few months of onset motivates the development of a rapidly scalable vaccine.These data support further development of LION/repRNA-CoV2S as a vaccine candidate for prophylactic protection from SARS-CoV-2 infection.These data provide insight into the vaccine design and evaluation of immunogenicity to enable rapid translation to the clinic."}